Orphenadrine
- Atc Codes:M03BC01
- CAS Codes:4682-36-4#83-98-7
- PHARMGKB ID:4682-36-4#83-98-7
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Cyprus: Norflex; Denmark: Lysantin; Finland: Norflex; Germany: Norflex; Greece: Norflex; Italy: Disipal; Luxembourg: Disipal, Norflex; Sweden: Norflex; UK: Biorphen, Disipal, Orphenadrine.
North America
Canada: Norflex, Orfenace, Orphendrine; USA: Disipal, Norflex, Orphenadrine.
Latin America
Mexico: Norflex.
Drug combinations
Orphenadrine and Acetaminophen
Orphenadrine and Nimesulide
Orphenadrine and Propyphenazone
Orphenadrine, Aspirin, and Caffeine
Chemistry
Orphenadrine Citrate: C~18~H~23~NO C~6~H~8~O~7~. Mw: 461.50. (1) Ethanamine, N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-, (±)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1); (2)(±)-N,N-Dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine citrate (1:1). CAS-4682-36-4; CAS-83-98-7 (orphenadrine).
Pharmacologic Category
Skeletal Muscle Relaxants, Miscellaneous, Anticholinergic Anti-Parkinson’s Agent. (ATC-Code: M03BC01).
Mechanism of action
Indirect skeletal muscle relaxant with some euphorigenic and analgesic properties. CNS depressant. May reduce skeletal muscle spasm through atropine-like central action on cerebral motor centers or on medulla. Exhibits postganglionic anticholinergic, antihistaminic, and local anesthetic properties.
Therapeutic use
Muscle spasm associated with acute painful musculoskeletal conditions.
Pregnancy and lactiation implications
Animal reproduction studies not conducted. There are to date no adequate studies in pregnant women. Use during pregnancy only if clearly needed. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to orphenadrine or any component of the formulation. Glaucoma. Gastrointestinal obstruction, stenosing peptic ulcer. Prostatic hypertrophy, bladder neck obstruction. Cardiospasm. Myasthenia gravis.
Warnings and precautions
May cause CNS depression. Use with caution in heart failure, cardiac decompensation, coronary insufficiency, tachycardia, or cardiac arrhythmias. Use with caution if history of drug abuse or acute alcoholism (potential for abuse exists). Injection contains sodium bisulfite which may cause allergic reaction in some individuals.